Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yasmin Karimi, Julie Vose, Michael Roost Clausen, David Cunningham, Umar Farooq, Tatyana A. Feldman, Hervé Ghesquieres, Wojciech Jurczak, Kim M. Linton, Tycel Jovelle Phillips, Won Seog Kim, Pegah Jafarinasabian, Milan Geybels, David Soong, Barbara D'Angelo Månsson, Christian Eskelund, Mohammad Atiya, Martin Hutchings, Catherine Thieblemont, Chan Cheah
Institutions: University of Michigan, University of Nebraska Medical Center, Vejle Sygehus, Royal Marsden NHS Foundation Trust, University of Iowa, Hackensack Meridian Health, Hackensack Meridian School of Medicine, Hospices Civils de Lyon, Hôpital Lyon Sud, University of Manchester, The Christie NHS Foundation Trust, Cancer Research UK Manchester Centre, U-M Rogel Cancer Center, Samsung Medical Center, AbbVie (United States), Genmab (Denmark), Genmab (United States), University of Copenhagen, Rigshospitalet, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, The University of Western Australia, Sir Charles Gairdner Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410819828